Synriam 150/750mg Tab

Synriam 150/750mg Tab represent a powerful and modern treatment for uncomplicated malaria infections, particularly caused by Plasmodium falciparum. This fixed-dose combination therapy is part of the Artemisinin-based Combination Therapy (ACT) protocol recommended by the World Health Organization (WHO). It is widely used in malaria-endemic regions across Asia and Africa and offers an effective, convenient, and patient-compliant treatment regimen.

Each tablet contains:

• Arterolane Maleate 150 mg – a synthetic ozonide antimalarial drug that acts quickly to kill malaria parasites during the early blood stages.

• Piperaquine Phosphate 750 mg – a long-acting partner drug that helps maintain sustained plasma levels to prevent parasite recrudescence and relapse.

The combination provides fast symptom relief and full parasite clearance, even in areas with chloroquine-resistant or multidrug-resistant malaria strains. Arterolane has a fast onset of action, often relieving symptoms like fever, chills, and fatigue within the first 24–48 hours, while piperaquine offers long-lasting protection by preventing recurrence.

This once-daily, 3-day treatment greatly improves compliance and convenience, especially compared to older regimens requiring multiple daily doses.